CeVO4 nanoparticles and application thereof in glioma

CeVO4 nanoparticles prepared by hydrothermal method use their pH-dependent activity to kill tumor cells in GBM cells and repair damage in neuronal cells, solving the problem of brain damage after radiation treatment in GBM patients, realizing tumor killing and nerves The dual effect of meta protection.

CN118976046APending Publication Date: 2024-11-19SHANDONG UNIV QILU HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410860414.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Patients with glioblastoma (GBM) often experience irreversible brain damage after radiation therapy. Existing treatments are difficult to kill tumor cells and protect neuronal cells at the same time. Cognitive dysfunction caused by radiation therapy is the most common concurrent disease.

Method used

CeVO4 nanoparticles synthesized by hydrothermal method show pH dependence, superoxide dismutase (SOD) activity in neutral environment and peroxidase (POD) activity in acidic environment, and act on lysosomes. and mitochondria, achieving killing of GBM cells and protection of neurons.

Benefits of technology

CeVO4 nanoparticles cause cell damage and reactive oxygen accumulation in GBM cells, killing tumor cells; in neuronal cells, lysosomal escape and mitochondrial aggregation, reverse the mitochondrial damage caused by radiation, restore the expression of anti-apoptotic proteins, and achieve The dual effect improves the effect of radiotherapy and repairs brain damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976046A_ABST
    Figure CN118976046A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to CeVO4 nanoparticles and application thereof in glioma. Specifically, CeVO4 nanoparticles with a rod-like structure are synthesized by using a hydrothermal method, and tests prove that the CeVO4 nanoparticles can be used for treating glioblastoma and repairing brain injury after GBM ionizing radiation (IR). In GBM cells, the system acts on lysosome to cause cell damage and reactive oxygen species (ROS) accumulation; in neuronal cells, the nano-enzyme can reverse mitochondrial damage caused by IR through lysosome escape and aggregation of the nano-enzyme and mitochondria, and the expression level of anti-apoptosis BCL-2 protein is recovered. In the aspect of mechanism, the distribution difference is considered to be related to a specific uptake internalization mechanism and a lysosome repair pathway in neurons, and finally double effects of tumor killing and nerve repair in an in-vivo model are caused, so that the method has good potential practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a CeVO4 nanoparticle and an application thereof in glioma. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Glioblastoma (GBM) is one of the most malignant brain tumors of the central nervous system, and patients have a poor prognosis. The standard treatment for GBM includes oral chemotherapy drug temozolomide after surgery and concurrent radiotherapy (IR). Despite the simultaneous radiotherapy and chemotherapy, the median survival of GBM patients is only 14 months, and most patients eventually die from tumor recurrence. In addition, high-dose radiotherapy often causes irreversible brain damage. Studies have shown that approximately 50-90% of patients may exhibit radiation-induced brain injury (RIBI), among which cognitive dysfunction is the most common complication of RIBI. Therefore, it is particularly important to develop a drug that can both kill tumors and protect neurons after radiotherapy.

[0004] The effect of living cells on IR is mainly through the ionization of deoxyribonucleic acid (DNA), which leads to direct destruction of the atomic structure, resulting in the destruction of the intracellular molecular structure, and ultimately the formation of excessive reactive oxygen species to cause tumor killing. The level of superoxide in cells is strictly controlled by superoxide dismutase (SOD), which constitutes the first line of defense against antioxidant stress. On the other hand, peroxidase can catalyze the decomposition of hydrogen peroxide (H2O2) to produce highly toxic hydroxyl radicals, inducing cell apoptosis. However, most natural enzymes have poor biological stability and require suitable catalytic conditions to be active. Nanozymes are artificial enzymes based on nanomaterials and have higher catalytic stability than natural enzymes. Nanozymes have been rapidly developed in the biomedical field due to their stable structure, low susceptibility to external interference, and low synthesis cost. These unique nanoplatforms are widely used in the biomedical field, including tumor treatment and tissue repair. Studies have shown that nanozymes containing peroxidase mimics (POD-mimics) can induce apoptosis or necrosis of tumor cells. In addition, nanozymes with SOD enzyme activity have been used for neuronal protection, anti-atherosclerosis, anti-inflammation and other functions. Interestingly, some nanozymes show pH dependence. For example, Fe3O4NPs have pH-dependent dual enzyme activity under neutral pH conditions and exhibit catalase (CAT)-like activity that can scavenge ROS. Under acidic conditions, Fe3O4NPs exhibit peroxidase (POD)-like activity that can generate ROS. Their different enzyme activities can be used to treat different diseases. Therefore, it is crucial to explore the regulation of pH on nanozymes.

[0005] Unique nanozymes, such as cerium oxide nanoparticles (CeONPs), are a new generation of artificial enzymes that have attracted attention due to their excellent nanozyme activity, low toxicity, and ability to easily and significantly adjust their electronic configuration in response to changes in the biological environment. These properties are due to the Ce 4+ (completely reduced) and Ce 3+ The oxidation states between (complete oxidation) and (complete oxidation) can be quickly and easily converted to each other. CeVO4 is a vanadate with a structure of RVO4 type, where R is a rare earth element. This type of material contains Ce 4+ / Ce 3+ and V 5+ / V 4+ activation center, which can be widely used in photocatalysis, oxidative degradation and electroluminescence. CeVO4 nanozymes rely on the surface Ce 3+ / Ce 4+ ions, which is similar to the effect of CeO2. 3+ and Ce 4+Due to the mixed valence state and the presence of oxygen vacancies, CeO2 exhibits a variety of enzyme-like catalytic activities, including peroxidase (POD), catalase (CAT) and superoxide dismutase (SOD)-like activities, and CeO2 has potential biomedical applications as nanoparticle enzymes due to its excellent chemical stability, biocompatibility and extremely low Ce ion leaching. 3+ / Ce 4+ The ratio corresponds to a higher SOD simulation activity, and as Ce 3+ / Ce 4+ The ratio decreases, and the SOD mimicking activity is inhibited and transferred to CAT / POD mimicking activity. 3+ and Ce 4+ The mixed valence states of CeVO4 mediate the increase of reactive oxygen species, which depends on the acidic pH value, which also reveals the pH dependence of different enzyme activities of CeO2. However, the relevant nanozyme activities of CeVO4 are still unclear. Therefore, it is of great significance to clarify the biological application and expansion mechanism of CeVO4. Summary of the invention

[0006] In view of the problems existing in the above-mentioned prior art, the present invention aims to provide a CeVO4 nanoparticle and its application in glioma. Specifically, the present invention uses a hydrothermal method to synthesize CeVO4 nanoparticles with a rod-like structure, which has been experimentally verified to be useful for the treatment of glioblastoma and the repair of brain damage after GBM ionizing radiation (IR). Based on the above research results, the present invention is completed.

[0007] In order to achieve the above technical objectives, the technical solution of the present invention is:

[0008] In a first aspect, the present invention provides the use of CeVO4 nanoparticles in any one or more of the following:

[0009] (a1) preparing a product for killing glioma tumors;

[0010] (a2) Prepare products for repairing brain damage after ionizing radiation of glioma.

[0011] Wherein, the glioma may be a glioblastoma.

[0012] The product may be a drug or a test reagent, and the test reagent is specifically a common test reagent for non-medical use, so that it can be used to study the occurrence and development mechanism of tumors such as gliomas.

[0013] The CeVO4 nanoparticles can be prepared and synthesized by a hydrothermal method.

[0014] The second aspect of the present invention provides a product, which contains at least the above-mentioned CeVO4 nanoparticles.

[0015] The product has any one or more of the following effects:

[0016] (a1) preparing a product for killing glioma tumors;

[0017] (a2) Prepare products for repairing brain damage after ionizing radiation of glioma.

[0018] The third aspect of the present invention provides the use of the above-mentioned CeVO4 nanoparticles or products in the preparation of drugs for improving the radiotherapy treatment effect of glioma.

[0019] Among them, the improvement of the therapeutic effect of glioma radiotherapy is specifically manifested in: further promoting the killing of glioma cells, and at the same time being used for repairing brain damage after glioma radiotherapy.

[0020] A fourth aspect of the present invention provides a method for treating glioma, the method comprising: administering the above-mentioned CeVO4 nanoparticles or products to a subject.

[0021] Beneficial technical effects of one or more of the above technical solutions:

[0022] In the above technical scheme, a cerium vanadate (CeVO4) nanozyme for the treatment of glioblastoma (GBM) and the repair of brain damage after GBM ionizing radiation (IR) is synthesized. The nanozyme exhibits pH dependence: it exhibits strong superoxide dismutase (SOD) enzyme activity in a neutral environment and strong peroxidase (POD) enzyme activity in an acidic environment. In GBM cells, the system acts on lysosomes, leading to cell damage and accumulation of reactive oxygen species (ROS); in neuronal cells, the nanozyme can reverse mitochondrial damage caused by IR and restore the expression level of anti-apoptotic BCL-2 protein through lysosomal escape and nanozyme aggregation with mitochondria. Mechanistically, the present invention believes that this distribution difference is related to the specific uptake internalization mechanism and lysosomal repair pathway in neurons, ultimately leading to the dual effects of tumor killing and neural repair in the in vivo model. In summary, the above technical scheme provides new insights into the repair of brain damage after GBM radiotherapy and has good potential for practical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solution of the embodiment of the present invention, the drawings required for use in the description of the embodiment will be briefly introduced below. Obviously, the drawings in the following description are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0024] Figure 1 The schematic diagram of the catalytic treatment principle of CeVO4 of the present invention is shown in FIG. Under the action of ionizing radiation (IR), local injection of CeVO4 shows pH dependence, achieving targeted killing of glioma cells and protection of neurons.

[0025] Figure 2 The structure and composition characteristics of CeVO4 materials in the embodiments of the present invention. (a) TEM and HRTEM images of CeVO4 at different magnifications. (b) SEM image of CeVO4. (c) Raman spectrum of CeVO4 (de) XPS spectrum of vanadium atoms and oxygen atoms of CeVO4 nanorods. (f) XRD analysis of CeVO4 (JCPDS No-72-0282). (g) Changes in CeVO4 POD-like activity with pH value (2.6, 3.8, 4.0, 4.6, 5.0, 5.6, 6.5, 7.4, 8.0, 9.5). (h) POD-like activity diagram of CeVO4·OH reaction. (i) Relationship between the sod-like activity of CeVO4 and pH value (4.0, 4.6, 5.0, 6.5, 7.4). The inserted image shows the color change of blue formaldehyde. (j) Diagram of the lack of peroxidase-like activity of CeVO4 in different reaction systems. (k) The decrease in absorbance at 665 nm indicates that CeVO4 can degrade MB at acidic pH.

[0026] Figure 3 The subcellular localization of CeVO4 in different cells in the embodiments of the present invention. (a) Bio-TEM images of A172 and LN229 GBM cells incubated with CeVO4 nanozymes for 12 hours. (b) Bio-TEM images of LUHMES neuronal cells incubated with CeVO4 nanozymes for 12 hours. (c) FITC-labeled CeVO4 nanozymes colocalize with lysosomes (LysoTracker Red) or mitochondria (MitoTracker Red) in LN229GBM cells. (d) FITC-labeled CeVO4 nanozymes colocalize with lysosomes (LysoTracker Red) or mitochondria (MitoTracker Red) in LUHMES neuronal cells. Scale bar, 5 μm.

[0027] Figure 4(ab) Co-localization of FITC-labeled CeVO4 and lysosomes (LysoTracker Red) in LN229 and LUHMES neuronal cells at different time points in the examples of the present invention. Scale bar: 5 μm. (c) Various mechanisms and concentrations of inhibitors used in this study. (de) Flow cytometry results and quantitative analysis of the phagocytic effects of different inhibitors on CeVO4 in LUHMES and LN229 cells. (fg) Bio-TEM images of SH-SY5Y and SH-18SY5Y+RA (10 μM) cells incubated with CeVO4 nanozymes for 12 h. Scale bar, 500 nm.

[0028] Figure 5 Evaluation of the killing effect of CeVO4 on LN229 GBM cells in the examples of the present invention. (a) Calcein-AM (live cells) / PI (dead cells) staining of LN229 cells under different treatments (control, CeVO4, IR, IR+CeVO4). Scale bar, 50 μm. (b) Western blot analysis and quantitative analysis of BCL-2, BAX, and γ-H2AX protein expression under different treatments. Data are expressed as mean ± SD (n = 3) of γ-H2AX immunofluorescence staining (left) of LN229 cells with different treatments. The right figure shows the quantification of the average number of γ-H2AX foci. Scale bar, 5 μm. (d) Representative images of LN229 cells with different treatments and quantification of 21 comet assays. Scale bar, 100 μm. (e) DCFH-DA (ROS) staining of LN229 cells with different treatments (left). The right figure shows the quantification of fluorescence intensity. Scale bar, 5 μm. (f) Annexin VFITC / PI apoptosis flow cytometric analysis of LN229 cells under different treatments (left). The right panel shows the quantification of cell apoptosis rate (%). bf, data are presented as mean ± SD. Statistical significance was calculated using one-way ANOVA and post hoc Tukey's multiple comparison test. *p<0.05, **p<0.01, ***p<0.001.

[0029] Figure 6The neuroprotective effect of CeVO4 on LUHMES cells in the examples of the present invention was evaluated. (a) Western blot analysis and quantitative analysis of BCL-2 and BAX protein expression under different treatment conditions (control, si-NC, si-SOD1, siSOD1+CeVO4). (b) Western blot analysis and quantitative analysis of BCL-2 and BAX protein expression under different treatment conditions (control, DDC, DDC+CeVO4). (c) Western blot and quantitative analysis of BCL-2 and BAX protein expression under different treatment conditions (control, CeVO4, IR, IR+CeVO4). (d) Mitochondrial membrane potential and relative gray value after different treatments. Scale bar, 25μm. (e) Cell ATP levels were measured using a bioluminescence detection kit after 48h of transfection with different treatments (control, CeVO4, IR, IR+CeVO4).

[0030] Figure 7 In vivo evaluation of the anti-tumor and neuroprotective effects of CeVO4 in the embodiments of the present invention (a) Animal experiment timeline and schematic diagram. (b) Fluorescence images of orthotopic LN229-Luc+ human GBM tumor-bearing nude mice on day 0 and day 18. (c) Quantitative analysis of luminescence images (data are expressed as mean ± standard deviation, and statistical significance is calculated using one-way analysis of variance and post hoc Tukey's multiple comparison test. N = 5; *p < 0.05, ***p < 0.001, ****p < 0.0001 (compared with the saline treatment group). (d) Survival curves of mice in each group. Log-rank (Mantel-Cox) test was performed on the survival graph (n = 5). (e) H&E images of GBM tumors in different groups. (f) 27 representative Bcl-2 immunochemical images of xenograft GBM tumors in different groups. Scale bar, 50 μm. (g) NeuN and TUNEL images of neuronal cells in different groups. The above data are all expressed as mean ± standard deviation. Scale bar, 50 μm.

[0031] Figure 8 (a) The movement trajectories of mice in different treatment groups in the present invention. (bd) Statistical analysis of total walking distance, central zone dwell time, and central walking distance of different treatment groups. (e) T2-weighted MRI images of mice in different groups. Figure 8 bd, Data are presented as mean ± SD. Statistical significance was calculated using one-way ANOVA and post hoc Tukey's multiple comparison test. **p<0.01, **p<0.001. DETAILED DESCRIPTION

[0032] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0033] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0034] As mentioned above, high-dose radiotherapy often causes irreversible brain damage. Studies have shown that about 50-90% of patients may show radiation-induced brain damage, so it is particularly important to develop a drug that can both kill tumors and protect neurons after radiotherapy.

[0035] The present invention found in the GBM radiotherapy model treated with CeVO4 nanozymes that CeVO4 nanoparticles can not only protect neuronal cells from high-dose IR damage, but also kill tumor cells. Through further in-depth research, it was found that the nanozyme activity of CeVO4 nanoparticles is regulated by pH value, showing strong POD-like enzyme activity in acidic environment and strong SOD-like enzyme activity in neutral environment. In the acidic tumor microenvironment, a large amount of CeVO4 is enriched in endosomes, catalyzing the decomposition of H2O2 to generate hydroxyl radicals (·OH), releasing ROS to mediate tumor cell apoptosis. However, in the neutral environment of neuronal cells, CeVO4 escapes in the intracellular lysosomes, and the nanoparticles are mainly enriched in and around the mitochondria, preventing IR damage to neuronal cells by stabilizing the level of superoxide.

[0036] In view of this, in a typical embodiment of the present invention, the application of CeVO4 nanoparticles in any one or more of the following is provided:

[0037] (a1) preparing a product for killing glioma tumors;

[0038] (a2) Prepare products for repairing brain damage after ionizing radiation of glioma.

[0039] Wherein, the glioma may be a glioblastoma.

[0040] In (a1), the glioma tumor killing is specifically manifested as follows: the CeVO4 nanoparticles act on the lysosomes of glioma cells, exhibit POD enzyme activity in their acidic environment, and cause cell damage and accumulation of reactive oxygen species (ROS);

[0041] In (a2), the repair of brain damage after ionizing radiation of glioma is specifically manifested as follows: in neuronal cells, the nanoparticles reverse the mitochondrial damage caused by ionizing radiation and restore the expression level of anti-apoptotic BCL-2 protein through lysosomal escape and nanozyme aggregation with mitochondria.

[0042] The product may be a drug or a test reagent, and the test reagent is specifically a common test reagent for non-medical use, so that it can be used to study the occurrence and development mechanism of tumors such as gliomas.

[0043] Specifically, the CeVO4 nanoparticles have a nanorod-like structure, which exhibits pH dependence: it exhibits strong superoxide dismutase activity in a neutral environment and strong peroxidase activity in an acidic environment.

[0044] The CeVO4 nanoparticles can be prepared by hydrothermal method. The specific preparation method is as follows:

[0045] Ce(NO3)3 and EDTA are dissolved in water and stirred to obtain a mixed solution, and then Na3VO4 is added to the mixed solution, the pH is adjusted to alkaline, and then stirred for reaction, and the temperature is increased for hydrothermal reaction, and the product is obtained after purification.

[0046] Wherein, the molar ratio of Ce(NO3)3, EDTA and Na3VO4 is 1:0.1-10:0.1-10, preferably 1:1:1.

[0047] The specific conditions of the hydrothermal reaction are: maintaining at 160-200° C. for 1-36 hours, preferably maintaining at 180° C. for 18 hours. By controlling the above hydrothermal reaction conditions, CeVO4 nanoparticles with dual nanozyme activity are obtained.

[0048] Furthermore, the purification includes the steps of centrifugal separation and precipitation, and washing with water and ethanol.

[0049] In another specific embodiment of the present invention, a product is provided, wherein the product at least comprises the above-mentioned CeVO4 nanoparticles.

[0050] The product has any one or more of the following effects:

[0051] (a1) preparing a product for killing glioma tumors;

[0052] (a2) Prepare products for repairing brain damage after ionizing radiation of glioma.

[0053] Wherein, the glioma may be a glioblastoma.

[0054] In (a1), the glioma tumor killing is specifically manifested as follows: the CeVO4 nanoparticles act on the lysosomes of glioma cells, exhibit POD enzyme activity in their acidic environment, and cause cell damage and accumulation of reactive oxygen species (ROS);

[0055] In (a2), the repair of brain damage after ionizing radiation of glioma is specifically manifested as follows: in neuronal cells, the nanoparticles escape through lysosomes and localize in mitochondria, exert SOD enzyme activity, reverse mitochondrial damage caused by ionizing radiation, and restore the expression level of anti-apoptotic BCL-2 protein.

[0056] The product may be a drug or a test reagent, and the test reagent is specifically a common test reagent for non-medical use, so that it can be used to study the occurrence and development mechanism of tumors such as gliomas.

[0057] When the product is a drug, suitable excipients and additives can be added and prepared into different dosage forms using techniques known in the art, such as injections, lyophilized powder injections, liposome suspensions, tablets, gels, implants, etc., for administration by intravenous injection, local injection, implantation, inhalation, etc.

[0058] In another specific embodiment of the present invention, there is provided the use of the above-mentioned CeVO4 nanoparticles or products in the preparation of drugs for improving the radiotherapy treatment effect of glioma.

[0059] Among them, the improvement of the therapeutic effect of glioma radiotherapy is specifically manifested in: further promoting the killing of glioma cells, and at the same time being used for repairing brain damage after glioma radiotherapy.

[0060] The glioma includes glioblastoma.

[0061] In another specific embodiment of the present invention, a method for treating glioma is provided, the method comprising: administering the above-mentioned CeVO4 nanoparticles or products to a subject;

[0062] The glioma is glioblastoma. Furthermore, the subject orally takes the chemotherapy drug temozolomide and undergoes synchronous radiotherapy after surgery, and the above-mentioned CeVO4 nanoparticles or products are administered during the radiotherapy.

[0063] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0064] Example

[0065] 1. Materials and Methods

[0066] Synthesis of CeVO4 nanorods: Ce(NO3)3·6H2O (1.0 mmol) and EDTA (1.0 mmol) were dissolved in H2O and stirred for 15 min, then Na3VO4 (1.0 mmol) dissolved in H2O (15 mL) was slowly added to the stirred mixture. Subsequently, the pH of the solution was adjusted to 9.0 with ammonia water and stirred for another 15 min. The reaction mixture was transferred to a 50 mL stainless steel autoclave, sealed, and stored at 180 °C for 18 h. After the autoclave was cooled, the precipitate was separated by centrifugation and washed several times with ddH2O and ethanol. Finally, the sample was dried at 80 °C for 10 h before characterization.

[0067] Characterization methods: Scanning electron microscope images were obtained by S-4800II (Hitachi, Japan). TEM images were obtained by JEM-2100 (Japan). High-resolution TEM (HR-TEM) images were obtained using Talos F200X (Thermo Fisher, USA). X-ray photoelectron spectroscopy (XPS) data were from Axis Supra (SHIMADZU, UK). XRD diffraction patterns were obtained using a D8 Advance Powder diffraction meter from Bruker, Germany, on which a Cu K-rbr sealed tube was installed. Particle concentration and particle size distribution were determined using ZetaView (particle Metrix, Germany).

[0068] Peroxidase-like activity of CeVO4: The oxidation of the peroxidase substrate 3,3',5,5'-tetramethylbenzidine (TMB) in the presence of hydrogen peroxide and nanorods was measured spectrophotometrically. The reaction mixture (1 ml) contained CeVO4 nanoparticles (1 mg / mL), TMB (100 μM) and H2O2 (100 μM) at different pH values.

[0069] SOD-like activity of CeVO4: (1) NBT method: The standard SOD activity of CeVO4 was determined using a SOD detection kit (BC0170, Solarbio LifeSciences, Beijing, China). The mechanism of this kit is to generate superoxide anions (O2 ·- ). O2 ·-Nitroblue tetrazolium (NBT) can be reduced to form methyl oxamide, which absorbs at 560nm; the darker the blue color of the reaction solution, the lower the SOD activity. Finally, the SOD enzyme activity value (U / g) was obtained by analyzing the absorbance at 560nm and the mass volume ratio of CeVO4. (2) WST-8 method: The WST-8 total superoxide dismutase assay kit (S0101S, Beyotime Biotechnology, Shanghai, China) was used to detect the standard SOD activity of CeVO4. WST-8 can react with superoxide anions (O2 ·- ) reaction to generate water-soluble formaldehyde dye. Since SOD can catalyze the dismutation of superoxide anions, this reaction step can be inhibited by SOD, so the activity of SOD is negatively correlated with the generation of formaldehyde dye. Since SOD can catalyze the dismutation of superoxide anions, this reaction step can be inhibited by SOD, so the activity of SOD is negatively correlated with the generation of dirty dye, so the enzyme activity of SOD can be calculated by the colorimetric analysis of WST-8 product. Absorbance is measured at 450nm.

[0070] Determination of hydroxyl radicals: Terephthalic acid (TPA) was used as a fluorescent probe to determine the generation of OH during the interaction between CeVO4 and H2O2. Terephthalic acid (TPA) reacts with hydroxyl radicals to generate highly fluorescent 2-hydroxyterephthalic acid. The excitation wavelength is 315nm and the emission wavelength is 425nm.

[0071] Cell lines: Human GBM cell lines LN229, A172, THP-1, and SH-SY5Y were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). GBM cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin. SHSY5Y was cultured in DMEM / F12 medium. THP-1 cells were cultured in RPMI 1640 medium. Lund human midbrain (LUHMES) human neuronal cells were purchased from the Global Bioresource Center (ATCC, USA). These cells were stored in the Thermo Scientific NuncEasYFlask TM Cell culture flasks, while differentiated LUHMES cells were plated in Thermo Scientific Nunc TM Cell culture dishes / Multidishes (Thermo Fisher Scientific).

[0072] IR treatment: GBM cells were subjected to in vitro radiotherapy experiments using IR (6 Gy). In the in vivo experiment, nude mice were injected with LN229 GBM cells and then received 4 doses of IR (3.5 Gy each).

[0073] Animal study: Four-week-old male thymic nude mice (SLAC Laboratory Animal Center, Shanghai, China) were housed under specific pathogen-free conditions at 24°C with a 12-h day-night cycle. For intracranial xenograft GBM transplantation, 5 × 105 LN229 Luci+GBM cells diluted with 10 μL PBS were injected into the right frontal lobe of each mouse. Animal experiment ethics approval license number: DWLL-2022-042. For the IR treatment group, mice were given four doses of IR (3.5 Gy each).

[0074] In vivo antitumor activity of CeVO4 nanozymes: CeVO4 was infused into active microosmotic pumps (1002W, 100 μl, pumping rate 0.25 μl / h, RWD, Shenzhen, China) and coupled to a brain infusion kit (BIic-3, RWD, Shenzhen, China). On day 7 after the tumor model was successfully established, the pump filled with CeVO4 was implanted into a subcutaneous pocket on the back of tumor-inoculated mice. A brain cannula (connected to the pump via a catheter placed subcutaneously along the neck) was inserted through the skull tumor and fixed using dental cement. When the pump was no longer active, it was removed. No weight loss or other signs of toxicity were observed during the treatment period. Animals with signs of complications were killed by cervical dislocation. Subsequently, the perfused mice underwent brain resection, followed by H&E and immunohistochemistry (IHC) staining of brain and tumor tissues.

[0075] In vivo neuron protection validation: TUNEL and NeuN immunofluorescence staining were used to evaluate the neuron protection of CeVO4 nanozyme. Briefly, paraffin sections of the one-step TUNEL apoptosis assay kit (Beyotime Biotechnology, China) were first stained with TUNEL according to the manufacturer's protocol. NEUN (66836-1-lg, Proteintech) staining was performed with reference to the paraffin section immunofluorescence step. Images were taken with a confocal microscope (Leica SP8).

[0076] Open field test (OF): The open field test was performed after 4*3.5Gy infrared irradiation. Each mouse was placed in the center of the open field apparatus (Jiliang, DigBehv-MG, Shanghai, China). An 80 cm × 80 cm square, 10 cm away from the wall, was defined as the central area. The movement of mice was recorded for 10 min using a video imaging system (Jiliang, DigBehv-MG, Shanghai, China). The researchers analyzed the distance the mice walked and the time they stayed in the central area.

[0077] Statistical analysis: Each experiment was repeated at least 3 times independently. All data are expressed as mean ± SD (n = 3 or n = 5) and normalized to the respective control groups. The differences between the two groups were analyzed by Student's t test, and the differences between multiple groups were analyzed by one-way analysis of variance. The survival data of each group were determined by the Kaplan-Meier method and compared by the log-rank (Mantel-Cox) test. P values ​​were calculated using GraphPad Prism 7 software. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0078] 2. Results and Discussion

[0079] 2.1 Synthesis and characterization of CeVO4

[0080] CeVO4 nanoparticles were synthesized by hydrothermal method and the structures were analyzed by scanning electron microscopy (SEM) ( Figure 2 b) and transmission electron microscopy (TEM) ( Figure 2 a) The morphology of CeVO4 was characterized and it was found that CeVO4 has a rod-like structure. The high-resolution TEM (HRTEM) image of the tetragonal CeVO4 nanorods shows regular stripes ( Figure 2 a). CeVO4 was characterized by Raman spectroscopy. 857cm -1 The most intense peak at 789 cm can be assigned to the internal symmetric stretching mode ν1 (A1g). -1 The peak at 375 cm-1 and 469 cm-2 can be attributed to the asymmetric stretching mode ν3 (Eg). -1 Two bending modes are observed at Figure 2 c). The oxidation state of CeVO4 nanozymes was studied using X-ray photoelectron spectroscopy (XPS). Figure 2As shown in Figure 5, the peaks at 882.0eV (V0) and 885.8eV (V') belong to Ce3d5 / 2 transitions, and the peaks at 900.2eV (U0) and 904.3eV (U') belong to Ce3d3 / 2, indicating that Ce exists in the +3 oxidation state in CeVO4 nanozymes. The XPS spectrum of vanadium shows two strong peaks at 517eV and 524.7eV, belonging to V2p3 / 2 and V2p1 / 2, respectively, confirming the presence of vanadium in the +5 oxidation state. The phase of the material was determined by X-ray powder diffraction (XRD), and the diffraction peaks can be marked as Figure 2 f pure tetragonal (zircon type) CeVO4 phase (JCPDS No72-0282). The TMB (3,3', 5,5'-tetramethylbenzidine) method was used to study the function of CeVO4 nanorods in simulating POD enzymes. The oxidation of peroxidase substrate TMB by hydrogen peroxide and nanorods at different pH values ​​was determined by spectrophotometry. Figure 2 g and Figure 2 As shown in Figure j, the results confirmed that the POD-like enzyme activity of CeVO4 showed obvious pH dependence. At pH = 7.4, its activity was weak, but it showed strong POD-like enzyme activity at acidic pH. The possible reason is that the neutral or alkaline environment destroys the ionization balance of H2O2 in the aqueous solution and accelerates its decomposition into water and oxygen. Therefore, TPA was used as a fluorescent probe to confirm the generation of ·OH during the interaction between CeVO4 and H2O2. Figure 2 h, the results confirm that this process produces ·OH. In addition, Figure 2 The MB degradation experiment in k further confirmed the existence of ·OH in CeVO4 at acidic pH.

[0081] The SOD enzyme activity was determined by the nitroblue tetrazolium (NBT) method. ·- Nitroblue tetrazolium (NBT) can be reduced to generate formic acid, which absorbs at 560nm; the darker the blue of the reaction solution, the lower the SOD activity. Finally, by analyzing the 560nm absorbance and the mass volume ratio of CeVO4, the SOD enzyme activity value (U / g) is obtained. Figure 2 As shown in Fig. 1, at pH = 7.4, the SOD activity of CeVO4 is about 1938 U / g. The change of SOD-like activity with pH value is not as significant as that of POD-like activity.

[0082] 2.2 Differential distribution of CeVO4 in neurons and GBM cells

[0083] Subcellular localization of nanozymes is a key factor in determining which enzyme is active. The same nanozymes play different roles in different cells and have been studied. Fe3O4 NPs have pH-dependent dual enzyme activity under neutral pH conditions, showing CAT-like enzyme activity that can scavenge ROS, but under acidic conditions, Fe3O4 NPs show POD-like enzyme activity that can generate ROS. Therefore, combined with the measurement of CeVO4 enzyme activity at different pH values, it is speculated that CeVO4 will also produce the same phenomenon. The main function of mitochondria is to provide energy and is the main site for energy production in aerobic respiration. Therefore, some nanozymes can exert SOD enzyme activity by generating lysosomal escape targeting mitochondria to relieve hypoxia and eliminate excess ROS. Lysosomes are organelles within cells that can break down biomacromolecules such as proteins, nucleic acids, and polysaccharides. Different nanomaterials have been developed and need to achieve lysosomal-targeted tumor killing. To further verify the effects of two different cell types on CeVO4, the subcellular localization of the materials was detected by cell transmission electron microscopy. Subsequent experiments used glioma cell lines LN229 and A172 and neural cell line LUHMES. LN229 and A172 are typical GBM cell lines, and LUHMES are immortalized precursor cells that express dopaminergic neuron characteristics through specific stimulation and differentiation. 100 μg / ml CeVO4 was incubated with LN229 and A172 cells for 12 hours. Figure 3 The biological transmission electron microscopy results of a show that CeVO4 is engulfed by GBM cells and the nanozymes are located in the lysosomes. In contrast, in HUHMES cells, there is no monolayer structure around the nanozymes, and a large number of nanozymes are enriched around the mitochondria ( Figure 3 b). The results were confirmed by confocal microscopy with mitochondrial probes (MitoTracker Red) or lysosomal probes (LysoTrackerRed), and CeVO4 was labeled with FITC. Lysosomal and mitochondrial fluorescent probes can penetrate the cell membrane and can be used for specific fluorescent staining of lysosomes or mitochondria in living cells. Confocal images showed that CeVO4 nanozymes colocalized with lysosomes 12 hours after addition to GBM cells ( Figure 3 c) However, in LUHMES neuronal cells, most of the nanozymes escaped from lysosomes and colocalized with mitochondria, showing preferential accumulation in mitochondria ( Figure 3 d).

[0084] 2.3 Reasons for the difference in distribution between neurons and GBM cells

[0085] In order to further explain this distribution difference phenomenon, relevant experiments were conducted. First, a time gradient experiment was established to detect the time points of CeVO4 uptake in LUHMES cells and GBM cells. Figure 4As shown in ab, in LN229 GBM cells, significant colocalization of CeVO4 with lysosomes was observed within 1-24 hours. In LUHMES neuronal cells, the study found that FITC-labeled CeVO4 was mainly localized in lysosomes within the first 4 hours. Interestingly, however, observations at 12 and 24 hours showed that it subsequently escaped from the confinement of lysosomes. It is speculated whether the mechanism of uptake and internalization is related to this phenomenon. Endocytosis is a key step for many therapeutic nanodrugs to reach intracellular targets. In order to elucidate the pathway by which CeVO4 is absorbed by cells, the classical endocytosis pathways of nanomaterials were referenced: clathrin-coated pore-mediated endocytosis (CME; fast endocytosis (FEME), CLIC / GEEC endocytosis (independent of clathrin and dynein), macrophage and phagocytosis. Their inhibitors were used to elucidate the internalization / uptake mechanism of nanozymes in GBM cells and neurons. The specific inhibitors and their mechanisms of action are as follows Figure 4 c. Subsequently, flow cytometry was used to detect the effects of different inhibitors on LN229-GBM cells and LUHMES neuronal cells. Figure 4 As shown in the figure, it was found that there was a significant difference in the uptake between neuronal cells and GBM cells. Dynasore had the greatest inhibitory effect on CeVO4 uptake in LUHMES cells, but there was no significant difference between Dynasore and Chloroqunie in LN229 cells, suggesting that FEME pathway-mediated endocytosis in neuronal cells played an important role. FEME, a clathrin-independent but ligand-driven specific membrane protein rapid endocytosis pathway, has recently become an important pathway for the rapid endocytosis of specific transmembrane receptors and is important in growth factor signaling and cell migration. In a 2015 NATURE article, it was mentioned that "Possibly, this will extend to growth cones and synapses in neurons, where rapid clathrin-independent endocytosis has been reported", indicating that the specificity of the FEME pathway is an important pathway in neurons. More interestingly, several recent articles have also confirmed that the FEME-mediated endocytosis pathway plays an important role in ultrafast endocytosis in neurons. Therefore, it is believed that the TEME pathway may be important for the differential distribution of CeVO4 in GBM cells and neuronal cells. In order to further support the conclusion, other neuronal cells were chosen for verification. The human neuroblastoma SH-SY5Y cell line is widely used in neurological research. In the undifferentiated state, SH-SY5Y cells do not fully express some characteristics of primary neurons. Through continuous treatment with retinoic acid (RA: 10μM), SH-SY5Y cells can be differentiated into a more mature neuron-like phenotype expressing mature neuronal markers. Bio-TEM detection was performed on differentiated and undifferentiated SH-SY5Y cells co-cultured with CeVO4 for 12 hours. Figure 4fg show that CeVO4 was enclosed by the outer membrane in undifferentiated SH-SY5Y cells, whereas CeVO4 showed a lysosomal escape pattern and was enriched in the mitochondrial region, except in RA-differentiated SH-SY5Y cells.

[0086] In summary, the difference in CeVO4 nanozyme expression between neurons and GBM cells can be attributed to two main factors. First, neuronal cells have a unique endocytosis mechanism, called the FEME pathway, which may be related to the unique growth cones and synapses of mature neurons. This mechanism promotes the rapid endocytosis of CeVO4 by mature neurons and subsequently mediates its escape from lysosomes. Second, the difference in lysosomal repair mechanisms between GBM and mature neuronal cells increases the possibility of CeVO4 nanozyme escape. Therefore, CeVO4 nanozyme finds it easier to escape in mature neuronal cells and ultimately targets damaged neuronal mitochondria.

[0087] 2.4 In vitro therapeutic effect of CeVO4 on GBM cells

[0088] In the in vitro GBM cell killing experiment, an IR treatment group was established, and CeVO4 was used to evaluate the synergistic therapeutic effect of IR and nanozymes. The experiment set up a control group, a CeVO4 (100 μg / ml) group, an IR (6 Gy) group, and an IR+CeVO4 group. Radiotherapy kills cancer cells by causing extensive DNA damage to irradiated cells; therefore, a series of experiments were conducted to further confirm the role of CeVO4 and determine whether IR works synergistically with CeVO4. The live / dead cell staining method was used to observe the cell death rate. Live cells were stained with calcein AM (green), and dead cells were stained with propidium iodide (PI) (red). Figure 5 As shown in a, the cell death rate increased significantly after incubation with CeVO4 and simultaneous IR treatment. The Bcl-2 family includes anti-apoptotic and pro-apoptotic components. The BCL2 family can be divided into two categories: pro-survival proteins with structures similar to Blc2, such as Bcl-XL; and pro-apoptotic proteins with structures similar to Blc2 and Bcl-XL, such as BAX and BAK, which function to block pro-survival proteins. Western blot was used to detect the expression of anti-apoptotic protein BLC2 and pro-apoptotic pore-forming protein BAX. The results showed that when IR and CeVO4 were used simultaneously, the expression of BCL2 was significantly reduced and the expression level of BAX protein was increased ( Figure 5 b). Annexin V-FITC / PI was used to detect cell apoptosis using flow cytometry ( Figure 5 f), it was found that the percentage of cell apoptosis in the IR+CeVO4 group was the highest, about 40%. In addition, γ-H2AX was used to measure the DNA damage level, and according to the WB protein level ( Figure 5 b) and immunofluorescence results19( Figure 5c), it was also found that the degree of DNA damage associated with IR and nanozymes was the greatest. The comet assay was used to detect the degree of DNA damage, and the results were similar to those of γ-H2AX ( Figure 5 d) To investigate the role of nanozymes in POD-like enzyme activity in GBM cells, the production of intracellular ·OH was detected using a DCFH-DA probe, which can react with ROS. Figure 5 As shown in Figure e, the fluorescence intensity of the IR and nanozyme treatment groups was higher, indicating that radiotherapy stimulation and nanozyme activity enhanced the production of ·OH. In summary, the above experiments confirmed that CeVO4 can act as a POD-like enzyme in GBM cells and work in combination with IR to kill tumor cells.

[0089] 2.5 The therapeutic effect of CeVO4 on neural cells in vitro

[0090] Interestingly, in neuronal cells, the effects of the nanozymes were reversed. Application of CeVO4 rescued the changes in BCL-2 and BAX expression induced by SOD1 siRNA ( Figure 6 a). In addition, diethyldithiocarbamate (DDC), a drug inhibitor of SOD1, was used to further verify the effect of CeVO4 nanorods. First, it was found that LUHMES cells underwent apoptosis after DDC treatment, and apoptotic proteins such as BCL-2 and BAX also underwent the same changes, but this phenomenon was restored after the use of CeVO4 nanorods ( Figure 6 b). These results confirm the ability of CeVO4 nanorods to mimic the SOD enzyme. Subsequently, the neuronal cells were treated with IR to verify the role of CeVO4 nanorods in neuronal radiotherapy damage after IR. IR is one of the most commonly used techniques for treating glioblastoma, but it may cause irreversible damage to nerve cells. In vitro radiotherapy experiments were performed on nerve cells using IR (6gy). Figure 6 As shown in Figure c, after IR treatment, BCL-2 and BAX protein levels changed accordingly, but CeVO4 nanorods rescued this change. Mitochondrial membrane potential is a functional mitochondrial parameter that reflects the health level of cells. After IR, neuronal cell DNA was damaged and mitochondrial membrane potential changed significantly, but the application of CeVO4 improved mitochondrial membrane potential and restored cell viability ( Figure 6 d) In addition, an ATP detection kit was used to detect the changes in intracellular ATP in different treatment groups, such as Figure 6 e. After IR treatment, ATP level was downregulated, but the use of CeVO4 nanorods could significantly restore ATP level.

[0091] 2.6 In vivo therapeutic effects of CeVO4

[0092] The present invention establishes a GBM radiotherapy and intratumoral administration of CeVO4 model for in vivo evaluation. Specifically, luciferase-labeled LN229 GBM cells were implanted in situ into the brain of immunodeficient nude mice (day 7). Seven days after tumor initiation, the nude mice were randomly divided into four groups. The four groups were saline injection group, CeVO4 injection group, IR group (4*3.5Gy) and IR+CeVO4 injection group ( Figure 7 a). All injections were performed with the assistance of a 9-day effective micro-osmotic pump (Figure S35). Similar to the in vitro experimental results, the bioluminescence images on day 18 showed that the tumor inhibition effect of the IR+CeVO4 group was the strongest ( Figure 7 b and 7c). The Kaplan-Meier survival curve of nude mice showed that the IR+CeVO4 group had the longest survival time ( Figure 7 d). Hematoxylin and eosin (H&E) staining showed that the tumor tissue in the IR+CeVO4 group was the smallest ( Figure 7 e). The expression of BLC2 protein in tumor tissues was also verified by immunohistochemistry, and the results showed that the expression of BCL2 was the lowest in the IR group ( Figure 7 f), which is consistent with the results of in vitro experiments. TUNEL assay is a valuable tool for detecting cell apoptosis, and NeuN is a classic nuclear marker of neurons. Immunofluorescence staining was used to determine the changes in neuronal damage after IR. The results showed that the neuronal damage caused by IR was alleviated in the IR+CeVO4 group ( Figure 7 g). These results suggest that CeVO4 applied in concurrent radiotherapy may be a possible means to kill GBM cells and treat patients with brain damage after IR.

[0093] The open field test is used to measure exploratory motor activity, and previous studies have shown that animals may show reduced activity, normal activity, or hyperactivity in the open field, depending on the severity and form of brain injury. Figure 8 adIt can be seen that in the IR group, due to the occurrence of RIBI, the exploration ability of mice was reduced, and they curled up in the peripheral area most of the time. However, in the IR+CeVO4 group, the number of mice entering the central area increased significantly, and the time they stayed in the central area was also significantly prolonged. MRI is one of the most effective means to evaluate and detect brain edema after radiotherapy. Mice in different treatment groups were examined using 3.0TMRI, such as Figure 8 As shown in Figure e, the T2-weighted images in the IR group showed obvious high signal intensity in the tumor area. In the saline, CeVO4, and IR groups, a slight shift of the tumor area with the midline was seen. Interestingly, after the combined use of CeVO4, the edema disappeared and the tumor was significantly reduced. This also provides useful evidence for the improvement of animal behavior.

[0094] In summary, this paper reports a CeVO4 nanozyme with dual nanozyme activity. Under neutral pH conditions, these nanozymes exhibit SOD-like enzymatic activity and are able to scavenge O2 ·- ; Under acidic conditions, they exhibit POD-like enzyme activity and are able to produce ·OH. These different enzyme functions can be found in normal cells (neuronal cells) compared to abnormally proliferating cells (GBM cells). In GBM cells, CeVO4 targets lysosomes, exhibits POD enzyme activity in the acidic environment of lysosomes, and kills tumor cells. In neuronal cells, CeVO4 escapes through lysosomes and localizes to mitochondria, exerting SOD enzyme activity, thereby rescuing mitochondrial damage caused by IR. Lysosomal repair function plays a vital role in this process. Related studies have revealed a new paradigm for the treatment of radiation brain damage and provided ideas for the application of CeVO4 nanozymes.

[0095] It should be noted that the above examples are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention is described in detail with reference to the given examples, those skilled in the art may modify or replace the technical solution of the present invention as needed without departing from the spirit and scope of the technical solution of the present invention.

Claims

1. Application of CeVO4 nanoparticles in any one or more of the following: (a1) preparing a product for killing glioma tumors; (a2) Prepare products for repairing brain damage after ionizing radiation of glioma.

2. The use according to claim 1, characterized in that: The glioma is glioblastoma.

3. The use according to claim 1, characterized in that: In (a1), the glioma tumor killing is specifically manifested as follows: the CeVO4 nanoparticles act on the lysosomes of glioma cells, exhibit POD enzyme activity in their acidic environment, and cause cell damage and accumulation of reactive oxygen species.

4. The use according to claim 1, characterized in that: In (a2), the repair of brain damage after ionizing radiation of glioma is specifically manifested as follows: in neuronal cells, the nanoparticles reverse the mitochondrial damage caused by ionizing radiation and restore the expression level of anti-apoptotic BCL-2 protein through lysosomal escape and nanozyme aggregation with mitochondria.

5. The use according to claim 1, characterized in that: The product is a medicine or a test reagent, and the test reagent is specifically a common test reagent for non-medical use.

6. The use according to claim 1, characterized in that: The CeVO4 nanoparticles can be prepared by hydrothermal method. The specific preparation method is as follows: Ce(NO3)3 and EDTA are dissolved in water and stirred to obtain a mixed solution, and then Na3VO4 is added to the mixed solution, the pH is adjusted to alkaline, and then stirred to react, and the temperature is increased to perform a hydrothermal reaction, and the mixture is obtained after purification; Further, the molar ratio of Ce(NO3)3, EDTA and Na3VO4 is 1:0.1-10:0.1-10; Furthermore, the specific conditions of the hydrothermal reaction are: maintaining at 160-200° C. for 1-36 hours; Furthermore, the purification includes the steps of centrifugal separation and precipitation, and washing with water and ethanol.

7. A product, characterized in that The product comprises at least CeVO4 nanoparticles in the application according to any one of claims 1 to 6; The product has any one or more of the following effects: (a1) preparing a product for killing glioma tumors; (a2) Prepare products for repairing brain damage after ionizing radiation of glioma.

8. Use of CeVO4 nanoparticles or the product described in claim 7 in the preparation of drugs for improving the radiotherapy effect of glioma.

9. The use according to claim 8, characterized in that The improvement of the therapeutic effect of glioma radiotherapy is specifically manifested in: further promoting the killing of glioma cells, and at the same time being used for repairing brain damage after glioma radiotherapy.

10. The use according to claim 8, characterized in that The glioma includes glioblastoma.